CFDE Data Portal | Search H2BC27P

	Label	Description
	H2BC27P Gene (Entity type)	ENSG00000181201 - H2B clustered histone 27, pseudogene
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	T62-Spleen Consensus Gene Set (Entity type)	A Gene Set from MoTrPAC
	GSE182680 GSE182683 dexamethasone 5 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE151083 enzalutamide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE225901 dexamethasone 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 5 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

H2BC27P

ENSG00000181201 - H2B clustered histone 27, pseudogene

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE114883 romidepsin T cell 1 v 4 human up

A Gene Set from LINCS

T62-Spleen Consensus

A Gene Set from MoTrPAC

GSE182680 GSE182683 dexamethasone 5 v 8 human dn

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human up

A Gene Set from LINCS

GSE151083 enzalutamide 0 v 1 human up

A Gene Set from LINCS

GSE225901 dexamethasone 0 v 1 human up

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 5 v 12 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.